Dear EditorSchistosomiasis is an infectious disease caused by trematode parasites of the genus
Schistosoma. According to the World Health Organization (WHO), at
least 206.5 million people required preventive treatment, of which more than 88 million
people were reported to have been treated
. Currently, three drugs are used for the treatment of schistosomiasis:
praziquantel, metrifonate, and oxamniquine. All three have a history of success at the
individual clinical level and in population or community-based chemotherapy
. However, praziquantel remains the drug of choice in humans because of its high
efficacy, low toxicity, and affordability. Currently, large-scale administration of
praziquantel (PZQ) is the main measure for controlling schistosomiasis, as recommended
by WHO focusing on morbidity control
.According to WHO, praziquantel is available in 600 mg tablets and must be administered
orally in a single dose of 40 mg/kg of body weight after a meal
. In some countries like Brazil, the Ministry of Health has its own guidelines.
In this country, the praziquantel dose is given according to the age group: children up
to 15 years old (60 mg/kg) and adults (50 mg/kg) of body weight
. Determining the treatment dosage by body weight using scales in a global
preventive program is considered problematic due to a substantial risk of technical and
systematic measurement errors
. In endemic areas, mainly in Africa, in order to facilitate treatment delivery,
WHO recommends to administer praziquantel using a dose-pole, calculating the appropriate
dosage by height instead of weight
. Studies have shown that height assessment rather than weighing scale in the
treatment of schistosomiasis using the dose pole is promising
,
. However, praziquantel must be administered between an acceptable dosage (30-60
mg/kg) and an ideal dosage (40-60 mg/kg). The under dosing of the drug could result in a
partial or inadequate treatment, as much as an over dosage could result in side-effects
such as abdominal pain, nausea and headache
,
. The dose-pole use is based on the individual height and does not take into
account individuals of the same height with different body weight. Baan et
al.
has shown, in African girls, that the use of the WHO pole dose is inaccurate in
dosing the appropriate amount of praziquantel in overweight/obesegirls. Thus, despite
the dose-pole benefits particularly in a poor resource scenario, following a regimen of
exposures to increasing amounts of PZQ, the development of a more accurate and
straightforward method for calculating the optimal dose to reduce the error of
weight-based treatment is urgently needed. Treatment performed in a large number of
patients in areas where the drug is still administered based on weight, such as in
Brazil, there is a grueling job of calculating adequate praziquantel dosing based on the
individual’s weight. Thus, we present a mobile device-app called PraziCalc which
facilitates and automatically calculates the optimal dosage of praziquantel based on the
patient’s body weight, ensuring the effectiveness oftreatment and the recommended
dosage.
The app system
We have developed a mobile-device app to simplify the calculation of praziquantel
dosage. The system is easy to use by any health worker, teacher, community
volunteeror drug distributor and it only requires a mobile device (e.g. smartphone,
tablet etc.). The app was created in 2017, it is free to all users, bilingual
(English/Portuguese) and available for iOS and android operational systems. The app
works as it follows: firstly, there is an initial screen where it is possible to
choose if the drug will be administrated according to the guidelines of the World
Health Organization (WHO) or the Health Ministry of Brazil (step 1). According to
WHO, praziquantel, which is available in 600 mg tablets, should be administered
orally in a single dose of 40 mg/kg of body weight
. In Brazil, the Ministry of Health has its own guideline. Praziquantel
dosage is prescribed according to the age group (children up to 15 years old or
adult - step 2) and body weight of the individual and administered orally in a
single dose of 50 mg/kg for adults and 60 mg/kg for children after a meal
. Subsequently, it is possible to entry the individual weight (step 3) and,
through a calculation (P x D / 600, where P is the weight and D is the dosage in mg
of the drug), the recommended amount of tablets that should be administered to each
patient (step 4) is informed. Figure 1
summarizes the steps to use the PraziCalc app.
Figure 1
Steps to use the PraziCalc mobile device-app: 1) choose if the drug
will be administrated according to the guidelines of the World Health
Organization or the Health Ministry of Brazil; 2) in Brazil,
praziquantel dosage is given according to the age group (children or
adult); 3) entry with the individual weight; 4) recommendation on the
amount of tablets that should be administered to the patient. Note: The
calculation example in the figure was according to WHO
guidelines
CONCLUSIONS
Through the use of this innovative mobile device-app, many benefits mau occur for
research in this area and for the infected population. Our purpose is to publicize
and make the PraziCalc app accessible to any health center that treats the disease
with praziquantel, facilitating the incorporation of this treatment process directed
to patients with schistosomiasis in endemic areas, who need preventive chemotherapy,
in medical clinics and in health centers. We believe this tool will assist the
medical and fieldwork teams in presenting a more dynamic, faster and safe method to
deliver praziquantel in the recommended dosage where the drug is still administered
based on body weight.
Authors: Chiquita A Palha De Sousa; Tracy Brigham; Bernard Chasekwa; Mduduzi N N Mbuya; James M Tielsch; Jean H Humphrey; Andrew J Prendergast Journal: Am J Trop Med Hyg Date: 2014-03-03 Impact factor: 2.345